Cell-free systems and the next wave of biomanufacturing IP

Biomanufacturing is undergoing a structural shift. For decades, engineered cells have been the dominant production platforms, but a new paradigm is emerging: cell free systems.

What is a cell-free system?

A cell-free system utilises the molecular machinery of life by extracting and repurposing it outside the cell, thereby avoiding the constraints of a living organism and removing the complexity of keeping the cell alive.

Given the correct instructions and materials, a cell-free system can synthesise a particular protein in a matter of hours, compared to the days or weeks often required by traditional cell-based approaches. The open nature of the system provides direct access to reaction conditions, allowing production processes to be readily monitored, sampled and optimised.

What does this mean for industry?

From an industry perspective, cell free systems sit at an attractive intersection of speed, flexibility and specialisation. Because there is no requirement to maintain cell viability, they can be used to produce proteins that would otherwise be toxic to a living host. They also significantly reduce development timelines by eliminating the need for repeated cell culture and passaging steps.

Cell-free systems also offer potential for local and on-demand manufacturing, which is particularly useful where a small volume of product is needed quickly, for example in the context of personalised vaccines. Because cell-free systems do not require living cultures, there is the potential for such systems to be freeze-dried, stored, and activated when needed.

Where is this technology going?

Cell-free technologies are rapidly expanding from laboratory tools into integrated manufacturing platforms.

While most commonly associated with protein production, cell-free systems can also be used to produce enzymes that can then be incorporated into wider manufacturing pathways. This shifts the technology from a protein expression tool towards a programmable manufacturing platform for chemicals, materials and therapeutics. Potential applications extend beyond therapeutic proteins to include flavour and fragrance compounds, cosmetic ingredients, industrial enzymes, advanced biomaterials and speciality chemicals.

More broadly, cell-free systems are increasingly being viewed as platform technologies rather than single-purpose manufacturing tools. Much like cloud computing provides a common infrastructure for many software applications, a single cell-free platform may ultimately be adapted to manufacture a diverse range of products simply by changing the underlying DNA templates, enzymes or reaction conditions.

As with many commercially relevant technologies, scale-up and standardisation will be critical to commercial success. This is where automation becomes increasingly important. Future cell-free manufacturing platforms may combine robotics, AI and lab-on-chip technologies to create highly automated biological foundries capable of rapidly designing, testing and optimising thousands of reactions in parallel. By integrating microfluidic devices that precisely control reactions at the microscale, such systems could significantly reduce development times while improving reproducibility and lowering costs.

The evolving IP landscape

As cell-free technologies move from research tools towards commercial manufacturing platforms, the associated patent landscape is becoming increasingly diverse.

Early patent activity focused on the foundational components of cell-free systems, including lysate preparation methods, reaction mixtures, energy regeneration systems and transcription-translation platforms. More recently, innovators have sought protection for engineered enzymes, metabolic pathways, non-natural amino acid incorporation technologies and methods for producing complex molecules such as antibody-drug conjugates and other therapeutic proteins.

Patent filings are also increasingly directed towards automation technologies, lab-on-chip devices, high-throughput screening platforms and integrated design-build-test-learn workflows. As a result, some of the most valuable intellectual property may ultimately reside not in individual products, but in the broader technology stack that enables their design, optimisation and manufacture.

The landscape includes established life-sciences companies seeking protection for core expression technologies, alongside specialist platform developers such as Sutro Biopharma and Nuclera, which are building proprietary ecosystems around cell-free manufacturing, automation and screening technologies.

The integration of cell-free systems with microfluidic and lab-on-chip technologies is also creating opportunities for hybrid patent portfolios spanning biology, engineering and software, further blurring the traditional boundaries between biotechnology and advanced manufacturing.

One of the key risks in this emerging landscape is a fragmented web of overlapping rights. Innovation is occurring across multiple layers, including core expression systems, engineered enzymes, manufacturing pathways, automation platforms, microfluidic devices and end products, increasing freedom-to-operate complexity. Broad platform claims may also give rise to overlapping claim scope and future validity challenges.

For innovators, a key strategic consideration is how best to protect value across multiple layers of the technology. Whilst patents remain important for core technologies, companies should also consider protecting automation workflows, data-driven optimisation methods and platform technologies that support a wide range of downstream applications. Given the increasing overlap between biological, engineering and software-based innovations, a combination of patents, trade secrets and know-how may provide the most robust protection.

Cell free systems are set to redefine key parts of the manufacturing chain. For IP, the implications are clear. This is not simply a new application area; it is a shift towards platform centric innovation, where control over enabling technologies may prove more valuable than ownership of individual products.